This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Tangpricha, V. Articles by Ziegler, T. R. Search for Related Content PubMed PubMed Citation Articles by Tangpricha, V. Articles by Ziegler, T. R. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB CALCIUM COMPOUNDS CALCIUM, ELEMENTAL Social Bookmarking                         What's this?

Growth Hormone Favorably Affects Bone Turnover and Bone Mineral Density in Patients With Short Bowel Syndrome Undergoing Intestinal Rehabilitation

Vin Tangpricha, MD, PhD^*,, Menghua Luo, MD^*,, Concepción Fernández-Estívariz, MD^*, Li H. Gu, MD^*, Niloofar Bazargan, MD^*, Jan-Michael Klapproth, MD^*, Shanthi V. Sitaraman, MD^*, John R. Galloway, MD, Lorraine M. Leader, MD^* and Thomas R. Ziegler, MD^*,

From the Departments of ^* Medicine and Surgery and Emory Center for Clinical and Molecular Nutrition, Emory University School of Medicine, Atlanta, Georgia

Correspondence: Thomas R. Ziegler, MD, Department of Medicine, Division of Endocrinology, Metabolism and Lipids, General Clinical Research Center, Room GG-23, Emory University Hospital, 1364 Clifton Road, Atlanta, GA 30322. Electronic mail may be sent to tzieg01{at}emory.edu.

Background: Patients with short bowel syndrome (SBS) have a high prevalence of metabolic bone disease due to nutrient malabsorption and potential effects of parenteral nutrition (PN). Human growth hormone (hGH) has been shown in some studies to have anabolic effects on bone, but hGH effects on bone in patients with SBS are unknown. Methods: Adults with PN-dependent SBS underwent a 7-day period of baseline studies while receiving usual oral diet and PN and then began receiving modified diets designed to improve nutrient absorption and daily oral calcium/vitamin D supplements (1500 mg elemental calcium and 600 IU vitamin D, respectively). Subjects were randomized to receive in a double-blind manner either subcutaneous (sc) saline placebo as the control or hGH (0.1 mg/kg/d for 3 weeks, then 0.1 mg/kg 3 days a week for 8 subsequent weeks). Open-label hGH was given from week 13 to week 24 in subjects who required PN after completion of the 12-week double-blind phase. Markers of bone turnover (serum osteocalcin and urinary N-telopeptide [NTX]), vitamin D nutriture (serum calcium, 25-hydroxyvitamin D [25-OH D] and parathyroid hormone [PTH] concentrations), and intestinal calcium absorption were measured at baseline and at weeks 4 and 12. Dual x-ray absorptiometry (DXA) of the hip and spine was performed to determine bone mineral density (BMD) at baseline and weeks 12 and 24. Results: The majority of subjects in each group exhibited evidence of vitamin D deficiency at baseline (25-OH D levels <30 ng/mL; 78% and 79% of control and hGH-treated subjects, respectively). Subjects treated with hGH demonstrated a significant increase from baseline in serum osteocalcin levels at 12 weeks (+62%; p < .05). The levels of NTX were increased over time in the hGH-treated group; however, this did not reach statistical significance. Both NTX and osteocalcin remained unchanged in control subjects. BMD of the spine and total hip was unchanged in subjects treated with placebo or hGH at 24 weeks. However, femoral neck BMD was slightly but significantly decreased in the placebo group at this time point but remained unchanged from baseline in the hGH-treated subjects. Conclusions: hGH therapy significantly increased markers of bone turnover during the initial 3 months of therapy and stabilized femoral neck bone mass over a 6-month period in patients with severe SBS undergoing intestinal rehabilitation.

Journal of Parenteral and Enteral Nutrition, Vol. 30, No. 6, 480-486 (2006)
DOI: 10.1177/0148607106030006480


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				T. R. Ziegler, M. Luo, C. F. Estivariz, D. A. Moore III, S. V. Sitaraman, L. Hao, N. Bazargan, J.-M. Klapproth, J. Tian, J. R. Galloway, et al. Detectable serum flagellin and lipopolysaccharide and upregulated anti-flagellin and lipopolysaccharide immunoglobulins in human short bowel syndrome Am J Physiol Regulatory Integrative Comp Physiol, February 1, 2008; 294(2): R402 - R410. [Abstract] [Full Text] [PDF]